ReviewFrontiers in immunology2026
Developing immunotherapies through glycosylation reprogramming to combat solid cancers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapies, including immune checkpoint inhibitors and adoptive cell transfer, have shown great efficacy and promise against hematological malignancies. However, the value of these therapies remains inconclusive in the context of solid cancers and is limited by several obstacles, including difficulty in identifying cancer-specific antigens, limited immune cell trafficking and infiltration into tumors, and the immunosuppressive effects of the tumor microenvironment. To further optimize the clinical effects of immunotherapies, many studies have focused on modifying metabolic programs, especially glycosylation, in cells. Glycosylation, which adds a diversity of carbohydrate structures (glycans) to surface molecules on virtually all cells, regulates stimulatory and inhibitory signaling pathways. Therefore, modification of key glycosylation pathways represents a logical approach for the development of new therapeutic strategies for treating solid cancers. We review how specific glycans regulate the anticancer activities of immune cells and immunosuppressive effects of cancer cells in cancer immunotherapy. In addition, we highlight T cells with NK cell properties
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.